August 5, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, August 5, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as

April 16, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, April 16, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that the U.S.

April 3, 2019 —Studies support synergistic role of p53 stabilization by APR-246 in combination with immuno-oncology agents   BOSTON, MA. and STOCKHOLM, SWEDEN, April 3, 2019 – Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade

March 25, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, March 25, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C.

February 27, 2019 —Janus Henderson Investors joins Investor Group   BOSTON, MA. and STOCKHOLM, SWEDEN, February 27, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced that funds managed

January 7, 2019 —BOSTON, MA., and STOCKHOLM, SWEDEN, January 7, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

December 2, 2018 — 95% ORR (by IWG) in 20 evaluable patients 70% complete remission (CR) rate in 20 evaluable patients No dose-limiting toxicities to date       BOSTON, MA. and STOCKHOLM, SWEDEN, December 2, 2018 – Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase

December 2, 2018 —BOSTON, MA. and STOCKHOLM, SWEDEN, November 30, 2018 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the closing of a EUR 50 million Series C financing round led by the

June 17, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all evaluable

April 16, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago   ORR (by IWG) of 100% in all